Uterine fibroid-treating device developer Mirabilis Medica raised $5 million in a new round of debt financing, according to an SEC filing posted today.
The company’s Mirabilis system is designed to use ultrasound to both provide imaging and ablation during procedures to remove uterine fibroids, the company said.
The device uses low-intensity ultrasound waves to locate fibroids within the body, and a high-intensity ultrasound to heat and kill the fibroid tissue to provide relief from symptoms due to the growths, according to the company’s site.
Money in the round came from 3 anonymous sources, according to the SEC filing. The company noted that the total offering amount does not include principal and accrued interest on previously issued convertible notes that converted into equity, including up to 5.1 million warrants issued with the financing.
The company has not yet stated how it plans to use the funds.
The $5 million takes the total raised for the company over the past handful of months up to $10.2 million, as it brought in $5.2 million in a round of debt financing in early June.